Sort
21,453 grants matching “tuberculosis”
Human immune signatures of latent MTB infection, active disease and BCG vaccination
$1,153,021Bjoern Peters · La Jolla Institute For Immunology · U19 · FY2015 · AI
TUBERCULOSIS ELIMINATION AND LABORATORY COOPERATIVE AGREEMENTS
$1,152,291Thomas Moore · South Carolina Department Of Public Health · U52 · FY2013 · PS
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway
$1,151,358Karen G. Anthony · L2 Diagnostics, Llc · U01 · FY2009 · AI
Innate Determinants of Microbial Immunity
$1,150,939Alan Sher · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
The Asia-Pacific HIV Observational Database (APHOD)
$1,150,713David A Cooper · Foundation For Aids Research · U01 · FY2007 · AI
Structures of Mtb proteins conferring susceptibility to known Mtb inhibitors
$1,150,586James C Sacchettini · Texas A&M University · U01 · FY2013 · GM
Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)
$1,150,146Larry S. Schlesinger · Texas Biomedical Research Institute · P30 · FY2023 · AI
Predicting immune responses that correlate with protection against tuberculosis
$1,149,943Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2016 · HL
Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)
$1,149,899Larry S. Schlesinger · Texas Biomedical Research Institute · P30 · FY2024 · AI
TUBERCULOSIS ELIMINATION AND LABORATORY
$1,149,772Nancy Baruch · Maryland State Department Of Health · U52 · FY2008 · PS
Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)
$1,149,653Larry S. Schlesinger · Texas Biomedical Research Institute · P30 · FY2025 · AI
Developing Teixobactin for Respiratory Infections
$1,147,950Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R01 · FY2023 · AI
Conditionally replicating Mycobacterium tuberculosis vaccines
$1,147,462Sabine Ehrt · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · AI
Synthesis of Therapeutic Agents for Treatment of Infectious Diseases
$1,146,607Walter Powell · Starks Associates, Inc. · N01 · FY2013 · AI
TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)
$1,146,372Payam Nahid · University Of California, San Francisco · R01 · FY2016 · AI
Integrating Structive Activity, Biokinetics and Response for ENP Risk Assessment
$1,146,151Brian D. Thrall · Battelle Pacific Northwest Laboratories · U19 · FY2014 · ES
International Tuberculosis Clinical Research
$1,145,241Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Collaborative Modeling for Assessment and Optimization in Public Health
$1,144,898Marc Lipsitch · Harvard School Of Public Health · U54 · FY2014 · GM
Production of Pedigreed SPF Rhesus Macaques
$1,144,683Jeffrey A Roberts · University Of California At Davis · U42 · FY2023 · OD
Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine
$1,144,476Richard Malley · Boston Children'S Hospital · R01 · FY2022 · AI
University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)-mRNA-1273-P204 Moderna Pediatric Study
$1,144,400Ann R Falsey · University Of Rochester · UM1 · FY2021 · AI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
$1,143,959Serena Patricia Koenig · Brigham And Women'S Hospital · U01 · FY2024 · AI
Sputum Transcriptomic Expression Profiling in Study 31: Express 31
$1,143,898Payam Nahid · University Of California, San Francisco · R01 · FY2017 · AI
East Africa IEDEA Regional Consortium
$1,143,702Constantin T Yiannoutsos · Indiana Univ-Purdue Univ At Indianapolis · U01 · FY2007 · AI
TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)
$1,142,366Payam Nahid · University Of California, San Francisco · R01 · FY2017 · AI